🇺🇸 FDA
Patent

US 10682310

Therapeutic compounds and formulations for intranasal delivery

granted A61KA61K31/417A61K31/5517

Quick answer

US patent 10682310 (Therapeutic compounds and formulations for intranasal delivery) held by Regents of the University of Minnesota expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/417, A61K31/5517, A61K38/4813, A61K38/482